MetaCap

Alpha Tau Medical (DRTS) vs PROCEPT BioRobotics (PRCT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Alpha Tau Medical (DRTS) has outperformed PROCEPT BioRobotics (PRCT) over the past year, gaining 207.7% versus a loss of 17.3%. Over five years, DRTS leads with a +18.5% price change compared with -30.6% for PRCT. PROCEPT BioRobotics is the larger company by market cap ($1.42 billion vs $1.09 billion), about 1.3 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DRTS+207.72%PRCT-17.28%
+323%+131%-62%
Nov 21, 20251 yearNov 20, 2026
DRTS+18.62%PRCT-39.28%
+155%+32%-90%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DRTS versus PRCT key metrics
MetricDRTSPRCT
Share price$11.76$24.70
Market cap$1.09B$1.42B
1-day change+3.93%-4.08%
YTD return+137.47%-21.49%
1-year return+207.72%-17.28%
5-year return+18.50%-30.64%
EPS (TTM)$-1.04$-2.02
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$308.05M
Revenue growth (YoY)—+37.22%
Net income (latest FY)$-42.63M$-95.57M
Gross margin—63.70%
Operating margin—-33.71%
Net margin—-31.02%
52-week high$15.79$38.11
52-week low$3.65$16.67
Distance from 52-week high-25.55%-35.19%
Analyst consensusstrong_buyhold
Avg. price target upside+75.24%-7.89%
Average volume591.88K1.31M
Shares outstanding92.48M57.54M
Employees121888
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • DRTS has outperformed PRCT by 225.0 percentage points over the past year.

About Alpha Tau Medical

DRTS stock →

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors.

Health Care · Medical/Dental Instruments · 121 employees

About PROCEPT BioRobotics

PRCT stock →

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia.

Health Care · Medical/Dental Instruments · 888 employees

DRTS vs PRCT FAQ

Which is bigger, Alpha Tau Medical or PROCEPT BioRobotics?

PROCEPT BioRobotics (PRCT) is larger, with a market capitalization of $1.42B compared with $1.09B for Alpha Tau Medical (DRTS).

Which stock has performed better over the past year, DRTS or PRCT?

DRTS returned +207.72% over the past 12 months, compared with -17.28% for PRCT (price return, excluding dividends). Past performance does not predict future results.

Are Alpha Tau Medical and PROCEPT BioRobotics in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons